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ABSTRACT

Luminescent semiconductor quantum dots (QDs) have recently been used for
delivering and monitoring biomolecules, such as drugs and proteins. However, QDs alone
have a very low efficiency of transport across the plasma membrane. In order to increase
the efficiency of QD delivery, synthetic nona-arginine (sR9) was used, a cell penetrating
peptide, to facilitate uptake. Data demonstrated that sR9 could significantly increase the
cellular uptake of QDs by noncovalent binding between QDs and sR9. Furthermore, the
mechanisms of QD/sR9 cellular internalization were investigated. Low temperature and
metabolic inhibitors markedly inhibited the uptake of QD/sR9, indicating that
internalization is an energy-dependent process. Several pathway inhibitors and the RNAi
technique were used to analyze the mechanism of uptake in live cell imaging studies.
siRNA knockdown demonstrated that clathrin-, and caveolin-dependent endocytosis were
not involved in QD/sR9 internalization. The conclusion is that the major routes of cellular
uptake involve macropinocytosis and lipid-raft dependent process.
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1. INTRODUCTION

Fluorescent semiconductor quantum dots (QDs) have been used to deliver and
monitor biomolecules into cells in the past few years (Hoshino et al., 2004; Bharali et al.,
2005; Michalet et al., 2005). Advantages of QDs over traditional dyes and proteins (e.g.,
GFP, RFP) include, but are not limited to, their unique physical and chemical properties
such as photostability, high quantum yield, narrow emission peak, exceptional resistance
to degradation, and broad size-dependent photoluminescence (Alivisatos et al., 2005;
Michalet et al., 2005). QDs properties such as multiplexing potential, photostability, and
inorganic nature make them useful for delivering or monitoring biomolecules in live cells.
However, although QDs could be engulfed into living cells, the intracellular
concentration of QDs is not very high (Xue et al., 2007). Therefore, recently bioconjugates or peptide-mediated QDs delivery were carried out to improve the
internalization.
Cell penetrating peptides (CPPs), also known as protein transduction domains
(PTDs) or membrane transduction peptides (MTPs), have been used for transduction of
biologically active proteins, siRNA, and drugs across plasma membranes (Dietz and Bahr
2004; Wang et al., 2007). The advantages of CPPs include ease of preparation, lack of
toxicity to the cell, and high efficiency of transduction (Tunnemann et al., 2008). CPPs
can enter cells in a half-time of 1.8 minutes, corresponding to a first-order rate constant k
of 0.007 sec-1 (Ziegler et al., 2005). Among many CPPs, the cellular uptake of
polyarginine tends to be more efficient than that of polylysine, polyhistidine or
polyornithine (Futaki, 2002). The highest translocation efficiency was reached by using
octa-arginine or nona-arginine peptides (Futaki, 2002). sR9 has been shown to effectively
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deliver not only covalently fused protein but also noncovalent mixed protein into
different types of animal and plant cells (Wang et al., 2006; Wang et al., 2007).
The exact mechanism of cellular entry of CPPs is still under vigorous debate.
Several reports previously showed that CPPs delivery of molecules into cells was
independent of endocytosis, energy, receptors, or active transporters (Schwarze et al.,
2000; Lindsay, 2002; Wadia and Dowdy, 2002). Later, it was found that fixing cells
might have artificially transduced molecules across plasma membranes. More recent
studies with live cell imaging suggested the mechanisms may involve macropinocytosis
(Snyder and Dowdy, 2004; Chang et al., 2007).
The uptake mechanism of QDs is less-well studied. By using specific inhibitors,
Ruan et al. identified macropinocytosis, actin filaments, and microtubules as required for
of internalization and intracellular transport for streptavidin-coated QD/Tat-biotin in
HeLa cells (Ruan et al., 2007). Zhang et al. demonstrated that carboxylic QDs were
internalized by lipid rafts dependent endocytosis in human epidermal keratinocytes
(HEKs), and these pathways were primarily regulated by the G-protein–coupled receptor
associated pathway and low density lipoprotein receptor/scavenger receptor (Zhang and
Monteiro-Riviere, 2009).
Our goals are to 1) test whether synthetic nona-arginine (sR9) can noncovalently
facilitate QD uptake and 2) investigate the internalization mechanism of QD/sR9. We
treated A549 cells with QDs alone and QD/sR9 complex, respectively, to demonstrate the
efficiency uptake of QDs at the aid of sR9. Inhibitors and siRNA were used to study
mechanism of uptake.
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2. REVIEW OF LITATURE

2.1. INTRODUCTION OF QUANTUM DOTS
Quantum dots are colloidal nanocrystals with unique optical properties that make
them outstanding fluorescent probes for long-term and multicolor imaging.
2.1.1. QD Anatomy. QDs consist of a semiconductor core, a passivation shell
(usually made of ZnS), and additional coatings. The core is composed of periodic groups
of II–VI (e.g. CdSe, CdTe, CdS, ZnSe), III–V (e.g. InP, InAs) or IV–VI (e.g. PbSe)
(Figure 2.1). The size of the core is 2 to 10 nm. Figure 2.2 shows the size comparison of
QDs and comparable objects. The size of QDs can increase dramatically depending on
the coating layer around the core. A thin layer of ZnS on the nanoparticle surface protects
the core from oxidation and increases the photoluminescence quantum yield (Michalet et
al., 2005; Maysinger et al., 2007). The charge of the nanoparticles is determined by polar
groups of the coating ligands and the surrounding pH.
QDs are mostly synthesized in nonpolar organic solvents, which make them
insoluble in water. Their hydrophobic surface ligands must be replaced by hydrophilic
ones for biological applications. QDs can also be prepared by water-based synthesis
method, which creates hydrophilic surface ligands around the core.
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(Maysinger et al., 2007)
Figure 2.1. Anatomy of QDs. Surface modifications of QDs provide protection of the
cores and QD targeting. Such modifications considerably enhance QD sizes.

(Michalet et al., 2005)
Figure 2.2. Size comparison of QDs and comparable objects. FITC, fluorescein
isothiocyanate; GFP, green fluorescent protein; qdot, green (4 nm, top) and red (6.5 nm,
bottom) CdSe/ZnS qdot; qrod, rod-shaped qdot (size from Quantum Dot Corp.’s Web
site). Three proteins—streptavidin (SAV), maltose binding protein (MBP), and
immunoglobulin G (IgG).
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2.1.2. Optical Properties. QDs have some unique optical properties, which make
them to be a much better imaging tool for delivering and monitoring biomolecules into
living cells.
2.1.2.1. Quantum dots have composition- and size-dependent absorption and
emission. QDs exhibit discrete size-dependent energy levels. As the size of the QDs
increases, the energy gap also increases, yielding a size-dependent rainbow of colors. The
color of QDs can be tunable, from ultraviolet to infrared, via varying the size and the
composition of QDs (Alivisatos et al., 2005; Michalet et al., 2005) (Figure 2.3).

(Bruchez et al., 1998)
Figure 2.3. Composition- and size-dependent absorption and emission. (A) Size- and
material-dependent emission spectra of several surfactant-coated semiconductor
nanocrystals in a variety of sizes. The blue series represents different sizes of CdSe
nanocrystals with diameters of 2.1, 2.4, 3.1, 3.6, and 4.6 nm (from right to left). The
green series is of InP nanocrystals with diameters of 3.0, 3.5, and 4.6 nm. The red series
is of InAs nanocrystals with diameters of 2.8, 3.6, 4.6, and 6.0 nm. (B) A true-color
image of a series of silica-coated core (CdSe)-shell (ZnS or CdS) nanocrystal probes in
aqueous buffer, all illuminated simultaneously with a handheld ultraviolet lamp.
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2.1.2.2. Unique optical spectra. Organic dyes typically have narrow absorption
spectra, which makes simultaneous excitation difficult in most cases. Furthermore, they
have asymmetric emission spectra broadened by a red-tail, making quantitation of
different probes difficult. In contrast, QDs have broad absorption spectra, enabling
excitation by a wide range of wavelengths, and their emission spectra are symmetric and
narrow (Figure 2.4.) (Alivisatos et al., 2005; Michalet et al., 2005). Consequently, QDs
can be excited with a single wavelength of light, resulting in multicolor that may be
detected simultaneously.

(Michalet et al., 2005)
Figure 2.4. Absorption and emission spectra of QDs. Absorption (upper curves) and
emission (lower curves) spectra of four CdSe/ZnS QD samples. The blue vertical line
indicates the 488-nm line of an argon-ion laser, which can be used to efficiently excite all
four types of QDs simultaneously.

2.1.2.3. Photostability. QDs have strong photostability due to their inorganic
composition, making them extremely resistant to photobleaching compared to organic
dyes (Figure 2.5.). This characteristic makes QDs very attractive probes for continuous
monitoring of biological phenomena.
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(Wu et al., 2003)
Figure 2.5. Photostability comparison between QDs and Alexa 488. Top row: nuclear
antigens were labeled with QD 630-streptavidin (red), and microtubules were labeled
with Alexa 488 conjugated to anti-mouse IgG (green) simultaneously in a 3T3 cell.
Bottom row: microtubules were labeled with QD 630-streptavidin (red), and nuclear
antigens were stained green with Alexa 488 conjugated to anti-human IgG.
2.1.2.4. Long luminescent lifetimes. Typically, the luminescent lifetimes of
organic dyes or auto-fluorescent proteins are a few nanoseconds. In contrast, the lifetime
of QDs is 10 to 40 ns (Alivisatos et al., 2005), which is significantly longer than organic
dyes. Such long lifetime greatly reduced background noises in live cell imaging.
Common organic dyes allow singlet–singlet electronic transition in a few nanoseconds.
Unfortunately, this prompt emission coincides with a high degree of short-lived
autofluorescence background from many naturally occurring species in a biological
specimen. Delayed (longlifetime) fluorescence labels for time-gated image and
fluorescence lifetime imaging have long been sought for enhanced contrast in cellular
imaging. However, because their fluorescence lifetime is too long, these probes have a
limited photon turnover rate and therefore limited sensitivity. QDs emits light slowly
enough that most of the autofluorescence background is over by the time emission occurs
but fast enough to maintain a high photon turnover rate. Therefore QDs may be ideal
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probes for spectrally multiplexed, time-gated cellular detection with enhanced selectivity
and sensitivity (Dahan et al., 2001).
2.1.3. Biological Applications. The first advantage of QDs is their utility as a
stable fluorescent marker for many purposes, including cancer diagnosis and treatment.
Wu et al. used QDs linked to streptavidin and antibody to detect the receptor Her2 on
SK-BR-3 breast cancer cells (Wu et al., 2003). Type II QDs emit light within the NIR
spectrum and have a potential surgical utility by providing optical guidance that can
result in reduction of cancer metastases (Soltesz et al., 2006). QD fluorescence can also
be used for sentinel lymph node (SLN) mapping and removal, which provides accurate
staging and therapeutic planning (Kim et al., 2004; Parungo et al., 2005a; Parungo et al.,
2005b; Soltesz et al., 2005; Soltesz et al., 2006). QDs properties such as multiplexing
potential, photostability, and inorganic nature make them useful for drug discovery. For
example, they allow monitoring of multiple drug candidates over extended time periods
in cell culture simultaneously, thus saving time and cost (Ozkan, 2004). Lai et al. used
surface-modified CdS QDs as chemically removable caps to retain drug molecules and
neurotransmitters inside mesoporous silica nanospheres. The CdS cap ensures the drug is
inside the system until released by disulfide bond reducing reagents (Lai et al., 2003;
Alivisatos et al., 2005).

2.2. INTRODUCTION OF CPPs
CPPs are peptides made of less than 30 amino acids. These CPPs are rich in arginine
and lysine residues. Positively charged amino acids, hydrophobicity and amphipathicity
are common features shared among many of the known CPPs.
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The three most widely studied CPPs are from the human immunodeficiency virus
type 1 (HIV-1) transcriptional activator Tat protein (Frankel and Pabo, 1988; Green and
Loewenstein, 1988), the Drosophila homeodomain transcription factor antennapedia
(Joliot et al., 1991), and the herpes simplex virus structural protein VP22 (Elliott and
O'Hare, 1997). Derived from HIV Tat peptide, many basic peptides have been generated,
such as Polyarginines, Pep-1, MPG, pVEC, SAP . These peptides and their variations can
covalently cross-link or noncovalently interact with a wide variety of biologically active
molecules up to 200 nm in diameter (Wadia and Dowdy, 2002).
Due to their low cytotoxicity and ability to carry multiple types of cargo, CPPs have
been used to improve delivery of many molecules such as small molecules,
oligonucleotide, plasmid DNA, peptide, protein, nanoparticle, lipid-based formulation,
virus, quantum dots. The number of applications using CPPs is consistantly increasing,
and so far more than 300 studies using either covalent or non-covalent CPP-based
strategies from in vitro to in vivo have been reported (Heitz et al., 2009).

2.3. INTRODUCTION OF ENDOCYTOSIS
Endocytosis is a basic cellular process that is used by cells to internalize a variety of
molecules. Endocytosis is the process of internalization of PM, ligands and fluid into the
cell, which can be divided into two main categories: phagocytosis or pinocytosis.
Phagocytosis takes place only in professional phagocytes such as macrophages,
monocytes and neutrophils, while pinocytosis occurs in most mammalian cell types
(Gong et al., 2008). Therefore, pinocytosis is called generally endocytosis, which can be
categorized into four different types: macropinocytosis, clathrin-dependent endocytosis,
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caveolae-dependent endocytosis or clathrin- and caveolae-independent endocytosis
(Conner and Schmid, 2003; Mayor and Pagano, 2007; Gong et al., 2008) (Figure 2.6.).

(Sandvig et al., 2008)
Figure 2.6. Overview of different types of endocytosis.

2.3.1. Clathrin-dependent Pathway. Clathrin-dependent pathway is the major
and best characterized endocytic pathway. Clathrin has specific trafficking motifs,
including the tyrosine-based motif, di-leucine-based motif, NPXY and mono-/multiubiquitination (Mousavi et al., 2004). These trafficking motifs are recognized by various
adaptor proteins, most notably the adaptor protein 2 (AP-2) (Gong et al., 2008). During
internalization, the adaptor proteins link the membrane cargo proteins to clathrin,
concentrating them in clathrin-coated pits. The clathrin-coated pits invaginate into the
cytoplasm, and eventually pinch off from the plasma membrane to form clathrin-coated
vesicles (80–120 nm in diameter) (Conner and Schmid, 2003).
The clathrin-dependent pathway is a highly regulated process. The assembly of the
clathrin lattice on the membrane is essential for the detachment of the vesicles. Drugs that
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dissociate clathrin and adaptor protein complex from membrane can inhibit this pathway.
The small GTPase dynamin is also very important for clathrin-dependent endocytosis
because it is required to facilitate the fission process (Damke et al., 1994). Therefore,
clathrin-dependent endocytosis requires energy.
2.3.2. Caveolea-dependent Pathway. Caveolae are a special type of lipid rafts.
Caveolea have a unique morphology of flask-shaped invaginations (50–80 nm in
diameter) on the cell surface (Conner and Schmid, 2003).
2.3.2.1. Caveolin-dependent endocytosis. Caveolae contain a high level of
caveolin proteins, including three caveolin isoforms: caveolin-1, caveolin-2, and
caveolin-3. Caveolin-1 and caveolin-2 are mainly found in non-muscle cells, while
caveolin-3 is expressed in skeletal and smooth muscle cells (Parton and Simons, 2007).
Cholesterol is required for caveolar uptake and drugs that bind to or sequester cholesterol
perturb internalization of caveolea (Schnitzer et al., 1994). Caveolar budding requires
Src-family kinases, dynamin and local actin polymerization (Sverdlov et al., 2007).
2.3.2.2. Flotillin-dependent endocytosis. Recent report shows that an alternative
caveolin-independent mechanism for making caveolae can somehow cause the formation
of caveolae. Flotillin 1 and flotillin 2 have similar topology to caveolin 1. Overexpression
of flotillin 1 and flotillin 2 in HeLa cells induced membrane curvatures and formation of
membrane invaginations morphologically similar to caveolae (Frick et al., 2007). These
flotillin-positive but caveolin-negative structures might be internalized by “classical”
caveolae (Frick et al., 2007; Hansen and Nichols, 2009).
2.3.3. Macropinocytosis. Macropinocytosis refers to the formation of large
endocytic vesicles of irregular size and shape, generated by actin-driven envagination of
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the plasma membrane (Swanson and Watts, 1995). A ruffle is formed by a liner band of
outward-directed actin polymerization near the plasma membrane. The endocytic vesicles
of macropinocytosis pathway, also known as macropinosomes, are formed through the
folding back and closure of membrane ruffle structures. Macropinosomes have no coat
and do not concentrate receptors. Macropinosomes are large vesicles with range from 1 to
5 µm in diameter (Conner and Schmid, 2003).
Ruffling is dependent on actin cytoskeleton. Therefore, drugs that disrupt the actin
cytoskeleton can inhibit macropinocytosis. The ruffling response is also dependent on
protein kinase C. Macropinocytosis can also be inhibited by amiloride and its analogs,
which inhibit the Na+/H+ exchange protein in the plasma membrane. Recent studies show
that macropinocytoiss is lipid-raft dependent process. Therefore, cholesterol depletion
can inhibit macropinocytosis.
2.3.4. Clathrin- and Caveolea-independent Pathways. The research on clathrinand cavoelea-independent endocytosis is still at an early stage. So far, there is still no a
satisfactory classification for those novel pathways. Recently, Mayor and Pagano
proposed two different classifications. According to the requirement of dynamin, these
pathways are divided into dynamin-dependent and dynamin-independent mechanism. A
second division is related to the involvement of small GTPases. Four different types are
subdivided by RhoA-regulated, cdc42-regulated, and Arf6-regulated endocytic pathway
(Mayor and Pagano, 2007) (Figure 2.6).
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3. MATERIAL AND METHODS

3.1. QUANTUM DOTS
CdSe/ZnS quantum dots (Adirondack Green, 520nm) were purchased from Evident
Technologies (Troy, NK, USA). These quantum dots have a PEG lipid surface coated
with carboxyl terminal groups. The emission and excitation peak wavelengths are 520 nm
and 505 nm respectively. The hydrodynamic diameter is 25 nm.

3.2. NONA-ARGININES (sR9)
Nona-arginines were synthesized by solid-phase peptide synthesis (Sigma-Aldrich,
Saint Louis, MO, USA). The synthesized peptides were purified by high performance
liquid chromatography (HPLC) using a reverse column. The purity of sR9 was up to 99%.

3.3. CHEMICALS
Fetal bovine serum, Ham’s F-12 medium with L-glutamine, trypsin-EDTA (1x),
Penicillin-streptomycin, sucrose, sodium azide, sodium fluoride, and chlorpromazine
were purchased from Fisher Scientific (Pittsburgh, PA, USA). Nystatin, filipin, 5-(Nethyl-N-isopropyl) amirolide (EIPA), Cytochalasin D (Cyt D), antimycin A, and
monodansylcadaverine (MDC) were obtained from Sigma-Aldrich.

3.4. CELL CULTURE
The human bronchoalveolar carcinoma-derived cell line (A549) was purchased from
ATCC (Manassas, VA, USA). Cells were maintained in Ham’s F-12 medium
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 µg/mL
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streptomycin, and grown at 37ºC in a 5% CO2 humidified environment. A549 cells were
seeded into 35 mm glass-bottom tissue culture plates (MatTek, Ashland, MA, USA) at an
initial confluency of 20%, and allowed to attach for 48 hours.

3.5. GEL RETARDATION ASSAY
The QD and sR9 complexes were prepared at different molecular ratios (1:10, 1:20,
1:30 and 1:60) and incubated for 20 min at room temperature to form noncovalent
binding between sR9 and QDs. These complexes were analyzed by electrophoresis in a
0.6% agarose gel in 0.5% TAE buffer at 130 voltages for 60 min. The gel was visualized
by UV light.

3.6. QD UPTAKE WITH sR9 AT DIFFERENT MOLECULAR RATIOS
To determine the optimal ratio between QD and sR9 for efficient delivery, A549
cells were incubated with QD/sR9 at different molecular ratios (1:10 to 1:60). The cells
were washed with ice-cold PBS for six times to remove unbound QD/sR9. Then
fluorescent image and quantitation were performed.

3.7. CYTOTOXICITY MEASURMENT
To determine the cytotoxicity of QD/sR9, A549 cells were treated with 12.5, 25, 50,
100, and 200 nM of QDs for 24 hours. Untreated cells served as a control group. The
MTS assay (Cell Titer 96® Aqueous One Solution Assay, Promega) was used to
determine cytotoxicity. Absorbance was measured at 490 nm using a microplate reader
(FLOURstat; BMG Labtechnonogies, Durham, NC, USA).
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3.8. QUANTUM DOTS AND sR9 NONCOVALENT BINDING AND
INTERNALIZATION
QDs were pre-mixed with sR9 peptides at the molecular ratio of 1:20 at room
temperature for 20 min. Immediately upon removal of medium from A549 cells, the cells
were treated with the QD/sR9 mixture at a final concentration of 150 nM for QDs for
designated period of time. After treatment, cells were washed with ice-cold PBS for six
times. Phenol red free medium (2 mL) (Invitrogen, Carlsbad, CA, USA) was added for
fluorescent image study.

3.9. UPTAKE STUDIES
To determine the mechanism of uptake, specific inhibitors of each type of uptake
pathway were selected. Table 4.1 lists all the inhibitors in our internalization studies.
3.9.1. Energy Inhibition. To determine whether uptake of QD/sR9 was energydependent, cells were incubated with QD/sR9 under varying metabolic conditions. For
low temperature studies, cells were treated at either 37ºC or 4ºC. For low temperature
group, cells were preincubated at 4ºC for 30min, and then cells were treated with QD/sR9
at 4ºC for another 1 hour. Treatment at 37°C was used as the control group. In metabolic
inhibition experiments, cells were incubated in the absence or presence of a mixture of
metabolic inhibitors (0.15% sodium azide, 15 mM sodium fluoride, and 2 µg/mL
antimycin A). Cells were pretreated with a mixture of metabolic inhibitors for 1 hour
followed by addition of QD/sR9 to the cells and then incubated for another 1 hour.
Table 4.1. Inhibitors for mechanistic studies on cellular uptake
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Inhibitor

Effect

Mechanism

References

Low

General inhibitor of Energy depletion

Vives, Brodin et al.

temperature

endocytosis

1997; Kaplan, Wadia
et al. 2005

Metabolic

General inhibitor of Energy depletion

Almofti, Harashima

inhibitors

endocytosis

et al. 2003; Khalil,
Kogure et al. 2006

Chlorpromazine Inhibitor of

MDC

Relocates clathrin

Wang, Rothberg et al.

clathrin-dependent

and adaptor protein

1993; Yao, Ehrlich et

endocytosis

complex 2 (AP2)

al. 2002

Inhibitor of

Stabilization of

Phonphok and

clathrin-dependent

nascent clathrin-

Rosenthal 1991;

endocytosis

coated vesicles

Panicker, Buhusi et
al. 2006

Hypertonic

Inhibitor of

Dissociation of

Hansen, Sandvig et

medium

clathrin-dependent

clathrin lattice

al. 1993

Cholesterol binding

Schnitzer, Oh et al.

endocytosis
Filipin

Inhibitor of lipidraft/caveolae

1994; Khalil, Kogure
et al. 2006

Nystatin

Inhibitor of lipid-

Sequester cholesterol Wadia, Stan et al.

raft/caveolae
EIPA

2004

Specific inhibitor

Inhibits the Na+/H+

Hewlett, Prescott et

of

exchange protein

al. 1994

Inhibitor of

F-actin

Cooper 1987; Wadia,

macropinocytosis

depolymerization

Stan et al. 2004

macropinocytosis
Cyt D

3.9.2. Clathrin-dependant Pathway Inhibition. To disrupt clathrin-dependent
endocytosis, hypertonic challenge, chlorpromazine, and MDC were used. Cells were
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pretreated with 0.45 M sucrose, 10 µM chlorpromazine, or 25 µg/mL MDC, respectively,
for 30 min, and then QD/sR9 were added to the cells followed by 1 hour incubation.
3.9.3. Caveolea-dependant Pathway Inhibition. To inhibit caveolea-dependent
endocytosis, filipin and nystatin were used to deplete cholesterol. Cells were
preincubated with 3 µg/mL filipin and 20 µg/mL nystatin, respectively, for 30 min before
treatment with QD/sR9 for another 1 hour.
3.9.4. Macropinocytosis Pathway Inhibition. EIPA (30 µM) or Cyt D (1 µg/mL)
was selected to block macropinocytosis. Cells were pretreated with these inhibitors for 30
min before treatment with QD/sR9 for another 1 hour.
3.9.5. siRNA Transfection. Due to potential nonspecific effects and toxicity of
inhibitors, clathrin heavy chain and caveolin-1 siRNA (Sigma-Aldrich) were used to
knockdown clathrin and caveolar pathways. The sense and antisense sequences of these
siRNA are as follows.
Clathrin HC: 5’-CCCUAAACACCUCAACGAU-3’ (sense)
5’-AUCGUUGAGGUGUUUAGGG-3’ (antisense)
Caveolin-1 5’-CAUUAUGACCGGGCUCAUA-3’ (sense)
5’-UAUGAGCCCGGUCAUAAUG-3’ (antisense)
Transfection of siRNA into the A549 cells were performed at a ~30% cell
confluence. siRNA was complexed with Lipofectamine 2000 reagent according to the
manufacturer’s instructions (Invitrogen). Western blot and QD/sR9 uptake studies were
conducted 3 days after transfection.

3.10. WESTERN BLOT ANALYSIS
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A549 cells were lysed in Lysis buffer (150 mM sodium chloride, 1.0% Triton X-100,
50 mM Tris, pH 8.0) containing 1% protease inhibitor cocktail (Sigma-Aldrich). The
protein concentration was quantified by the Bradford procedure (BioRad, Hercules, CA,
USA). Ten µg total cell protein was electrophoresed on 8% (clathrin-heavy chain) or
12% (caveolin-1) SDS-PAGE, followed by electrotransferring to a nitrocellulose
membrane. Clathrin-heavy chain was detected using a mouse monoclonal antibody at a
dilution of 1:200 and goat anti-mouse IgG-HRP secondary antibody (Santa Cruz, CA,
USA). Caveolin-1 protein was detected using a rabbit monoclonal antibody at a dilution
of 1:1000 and goat anti-rabbit IgG-HRP secondary antibody (Cell Signaling, Danvers,
MA, USA). The blots were probed with the ECL Western blot detection system
according to the manufacturer’s instructions (Thermo Fisher Scientific, Rockford, IL,
USA).

3.11. EPIFLUORESCENT MICROSCOPY
After treatment with QD/sR9, cells were viewed under the Olympus IX51 inverted
microscope at 600X total magnification using a UPLFLN 60X NA 1.25 objective
(Olympus, Center Valley, PA, USA). QD filter set (EX 435/40, EM 519-700) was used
for QDs (Semrock). Images were captured with a Hamamatsu ORCA285 CCD camera. Z
series images of entire cell volume were taken at 0.3 µm internals. Images were analyzed
by the SlideBook software (Intelligent Imaging Innovations, Denver, CO, USA).

3.12. STATISTICAL ANALYSES
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Data of fluorescent images were representatives of at least two independent
experiments. Fluorescent intensity was quantified by using the SlideBook software. Data
represented mean fluorescence intensity (after background subtraction) of a single plane
in Z series. One-tailed unpaired Student’s t-test was used for significance testing, using p
values of 0.01 and 0.05. Data were expressed as the mean ± standard deviation from 10
different fields performed in two independent experiments.
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4. RESULTS
4.1. FORMATION OF QD/sR9 NONCOVALENT BINDING
To test whether sR9 peptide could noncovalently bind to QDs, QDs were mixed
with sR9 at various molecular ratios (1:10, 1:20, 1:30 and 1:60). These mixtures were
separated by electrophoresis in a 0.6% agarose gel (Figure 4.1). The QD mobility was
reduced as the amount of sR9 increased. This result indicated that sR9 peptide interacted
with QDs and bound non-covalently.

Figure 4.1. Gel retardation analysis of the interaction between QDs and sR9. QDs
were pre-mixed with sR9 at different molecular ratios. Lane 1 showed QDs without sR9,
while Lanes 2-5 represented QDs mixed sR9 at ratios of 10, 20, 30 and 60 respectively.
The mobility was reduced as the amount of sR9 increased.

4.2. MOLECULAR RATIOS BETWEEN QD AND sR9 AFFECT UPTAKE
To determine the optimal ratio for cellular uptake, A549 cells were incubated with
QDs (150 nM) preincubated at different molecular ratios with sR9. Figure 4.2 shows that
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at ratio from 1:10 to 1:30, QD uptake was increased as the ratio of sR9 increased.
However, when the ratio was above 1: 30, the speed of internalization reached saturation.
In subsequent studies, we selected 1:20 as interaction ratio between QDs and sR9,
because this ratio provides good imaging quality.

Figure 4.2. QD uptake with sR9 at different molecular ratios. QDs were pre-mixed
with sR9 at molecular ratios (1:10 to 1:60). A549 cells were treated with QD/sR9. Error
bars represent the S.D. for 10 different fields performed in two independent experiments.
Fluorescence intensity is normalized relative to 1:10.

4.3. TIME DEPENDENT UPTAKE
To determine the optimal dosing time, A549 cells were incubated with QD/sR9 for 5
min, 20 min, 40 min, 1 hour and 3 hours. Figure 4.3 shows that the uptake of QD/sR9
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was dramatically increased after 20 min. At 1 hour, the uptake reached to the peak. Since
internalization was high at 1 hour, this time point was used for further experiments.

Figure 4.3. Time dependent uptake of QD/sR9. QDs were pre-mixed with sR9 at
molecular ratios (1:20). A549 cells were treated with QD/sR9 for 5 min, 20 min, 40 min,
1 hour and 3 hour, respectively. Error bars represent the S.D. for 10 different fields
performed in two independent experiments. Fluorescence intensity is normalized relative
to 5 min.
4.4. CYTOTOXICITY OF QD/sR9
To assess potential cytotoxicity caused by QD/sR9 complex, A549 cells were treated
with QD/sR9 (1:20) complex at various QD concentrations for 24 hours. No cytotoxicity
of QD/sR9 was observed at concentrations tested up to 200 nM (Figure 4.4).
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Figure 4.4. Cell viability of QD/sR9 treated cells. A549 cells were treated with QD/sR9
(1:20) for 24 hours. The concentrations of QDs used were: 12.5, 25, 50, 100 and 200 nM.
The cells treated with QD/sR9 showed a statistically insignificant difference from the
control group.

4.5. CELLULAR UPTAKE OF QDs FACILITATED BY sR9 PEPTIDE
To determine the ability of sR9 peptide to facilitate QD delivery, A549 cells were
treated with 150 nM QDs alone or 150 nM QDs premixed with sR9 at a ratio of 1:20.
After incubation of 5 min, 20 min, 40 min and 60 min, QDs treated cells were observed
under epifluorescence microscope. Figure 4.5 shows that the uptake of QD/sR9 was
statistical significantly increased above QDs alone at all time points. Uptake of the
QD/sR9 complex was extremely rapid, beginning at 5 min.
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A

B

C

QD/sR9

QDs

Figure 4.5. sR9 facilitate QD uptake. A: the relative fluorescence intensity of QDs.
A549 cells were treated with 150 nM QD and 150 nM QD/sR9 (1:20) for 5 min, 20 min,
40 min and 60 min respectively. Error bars represent the S.D. for 10 different fields
performed in two independent experiments. Significance indicated by: *p < 0.01 vs. QD
alone group. Fluorescence intensity is normalized relative to QD alone at 5 min. B and C:
the images of QDs’ uptake with and without sR9 after 1 hour treatment. Images represent
single plane of Z series.
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4.6. MECHANISM OF QD/sR9 INTERNALIZATION
Endocytosis, an essential cellular process of internalizing extracellular materials,
utilizes several distinct pathways. To determine the mechanism of sR9-mediated QD
delivery, a series of inhibition studies were carried out.
4.6.1. Energy Dependent Studies. To understand whether uptake of QD/sR9 was
mediated by energy-dependent endocytosis, we used low temperature or a mixture of
metabolic inhibitors to deplete intracellular energy. For the low temperature study, the
cells were incubated with QD/sR9 at 37°C and 4°C respectively. As shown in Figure 4.6b,
QD/sR9 internalization at 4°C was significantly impeded. Compared to 37°C, the
fluorescence intensity at 4°C decreased by 72% (p’s < 0.01). In the metabolic inhibition
study, A549 cells were incubated with QD/sR9 in the presence or absence of a mixture of
metabolic inhibitors (0.15% sodium azide, 15mM sodium fluoride, and 2µg/ml antimycin
A). As shown in Figure 4.6c, these metabolic inhibitors strongly inhibited the uptake of
QD/sR9. In comparison with the control group, the fluorescent intensity in the presence
of metabolic inhibitors decreased by 59% (p’s < 0.01) (Figure 4.6d).
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Figure 4.6. Energy inhibition reduced QD/sR9 internalization. A: the images of
control cells. B: the images of cells pre-treated at 4°C for 30 min, then incubated with
QD/sR9 for additional 1 hour. C: the images of cells pre-treated with metabolic inhibitor
mixture for 1 hour, then incubated with QD/sR9 for additional 1 hour. Images represent
single plane of Z series. D: mean fluorescence intensity. Error bars represent the S.D. for
10 different fields performed in two independent experiments. Significance indicated by:
*p < 0.01 vs. control.
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4.6.2. Clathrin-dependent Pathway. To perturb the clathin-dependent uptake
pathway, three methods were used: MDC, hyperotonic sucrose, and chlorpromazine. The
inhibitory activity of MDC is attributed to the stabilization of nascent clathrin-coated
vesicles, which limit new clathrin-coated vesicle production (Phonphok and Rosenthal,
1991). The underlying mechanism of hypertonic sucrose involves the dispersion of
clathrin lattices on the plasma membrane (Hansen et al., 1993). Chlorpromazine is a
cationic amphipathic drug that relocates clathrin and adaptor protein complex 2 (AP2)
from plasma membrane to endosomal membrane (Wang et al., 1993). MDC reduced the
uptake of QD/sR9 by 45% while hypertonic medium decreased uptake by 59% (data not
shown). Contrarily, chlorpromazine did not result in significant uptake reduction
compared to the control group (Figure 4.7).
4.6.3. Lipid-raft/Caveolea-dependent Pathway. Nystatin and filipin, lipid raft
inhibitors, are used to block caveolea-dependent endocytic pathway (Schnitzer et al.,
1994; Wadia et al., 2004). Treatment of cells with these two inhibitors moderately
reduced the QD/sR9 internalization by 36% and 35%, respectively (Figure 4.8) indicating
that a lipid raft-dependent process was involved in QD/sR9 internalization.
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Figure 4.7. Two different clathrin inhibitors produced different effects on QD/sR9
internalization. A: the images of control cells. B: the images of cells pre-treated with
chlorpromazine for 30 min, then incubated with QD/sR9 for additional 1 hour. C: the
images of cells pre-treated with MDC for 30 min, then incubated with QD/sR9 for
additional 1 hour. Images represent single plane of Z series. D: mean fluorescence
intensity. Error bars represent the S.D. for 10 different fields performed in two
independent experiments. Significance indicated by: *p < 0.01 vs. control.
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Figure 4.8. Lipid raft/Caveolea inhibition decreased QD/sR9 internalization. A: the
images of control cells. B: the images of cells pre-treated with nystatin for 30 min, then
incubated with QD/sR9 for additional 1 hour. C: the images of cells pre-treated with
filipin for 30 min, then incubated with QD/sR9 for additional 1 hour. Images represent
single plane of Z series. D: mean fluorescence intensity. Error bars represent the S.D. for
10 different fields performed in two independent experiments. Significance indicated by:
*p < 0.01 vs. control.

4.6.4. Macropinocytosis Pathway. EIPA is an inhibitor of Na+/H+ exchange
required for macropinocytosis (Hewlett et al., 1994). Cytochalasin D (Cyt D) is an Factin depolymerizing drug that caps the barbed or faster-growing ends of actin filaments
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(Cooper, 1987). The use of EIPA inhibited the uptake of QD/sR9 by 54% (Figure 4.9).
To confirm the effective concentration of Cyt D, we used Alexa 568 - phalloidin to stain
actin of Cyt D treated and control cells. At 1µg/ml, actin was successfully depolymerized
in A549 cells (data not shown). Cyt D reduced the uptake of QD by 11% (Figure 4.9).
Significant amount of condensed green fluorescent agglomerates were observed around
cellular surface (Figure 4.9c).
A

B

C

D

Figure 4.9. Macropinocytosis inhibition perturbed QD/sR9 internalization. A: the
images of control cells. B: the images of cells pre-treated with EIPA for 30 min, then
incubated with QD/sR9 for additional 1 hour. C: the images of cells pre-treated with Cyt
D for 30 min, then incubated with QD/sR9 for additional 1 hour. Images represent single
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plane of Z series. D: mean fluorescence intensity. Error bars represent the S.D. for 10
different fields performed in two independent experiments. Significance indicated by: *p
< 0.01 vs. control.

4.6.5. siRNA Knockdown. Considering potential nonspecific inhibition and
cytotoxicity of inhibitors, we further used the RNAi techniques to confirm the uptake
mechanisms. Clathrin HC and caveolin-1 siRNA were used to knockdown clathrindependent and caveolin-depedent pathway, respectively. Western blot demonstrated the
success of knockdown clathrin and caveolin-1 protein expression (Figure 4.10). In the
clathrin HC or caveolin-1 protein knockdown cells, the uptake of QD/sR9 was not
affected significantly (Figure 4.11). Clathrin siRNA data was in agreement with
chlorpromazine, which indicated that the uptake was not clathrin-dependent endocytosis.
Caveolin-1 siRNA data demonstrated that the caveolin-dependent pathway was not
involved in QD/sR9 internalization.
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Figure 4.10. Western blot analysis. A549 cells were treated with siRNA of clathrin HC
and caveolin-1 protein for 3 days, and then cells were lysed for western blot analysis. A:
clathrin HC protein expression in A549 cells. B: caveolin-1 protein expression in A549
cells. β-actin was used as the control.
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Figure 4.11. QD/sR9 uptake after knockdown of clathrin HC and caveolin-1 protein.
A549 cells were treated with siRNA of clathrin HC and caveolin-1 protein for 3 days, and
then cells were used for uptake studies. A: the images of control cells. B: the images of
cells pre-treated with clathrin HC siRNA. C: the images of cells pre-treated with
caveolin-1 siRNA. Images represent single plane of Z series. D: mean fluorescence
intensity. Error bars represent the S.D. for 5 different fields performed in two
independent experiments.
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5. DISCUSSION
Quantum dots are emerging as a new class of fluorescent probe for cellular imaging.
In comparison with organic dyes and fluorescent proteins, QDs have unique properties,
such as high quantum yield and photostability which make them better suited for
delivering and monitoring biomolecules. However, studies have shown that QDs are
slowly internalized into the cell. Our goal was to test whether nona-arginine (sR9) can
facilitate QD uptake and the mechanism of the uptake. Data from this study demonstrate
that QDs are rapidly internalized into A549 cells within 5 min with the aid of sR9 (data
not shown) while without the presence of sR9 QDs uptake is minimal. The enhancement
of internalization is thought to be due to an electrostatic interaction between cationic
nona-arginine and the negatively charged polar heads of the phospholipids of the plasma
membrane (Snyder and Dowdy, 2004). Our study demonstrates that sR9 increased QD
uptake up to 200nM without incurring toxicity.
QD/sR9 are internalized by endocytosis. In live cells, QD/sR9 internalization was
dramatically blocked by either low temperature or a mixture of metabolic inhibitors. This
indicated that the uptake of QD/sR9 was highly energy-dependent and supported that
endocytosis was a major uptake process. Subsequent studies were conducted to further
understand specific pathways of endocytosis.
Clathrin-dependent endocytosis is a well-characterized endocytic pathway. Treating
cells with hypertonic sucrose significantly reduced QD/sR9 uptake. Although this kind of
blockage is considered strong evidence of clathrin-dependent endocytosis, recent studies
have shown that it also interferes with other internalization pathways, such as caveoleadependent endocytosis and macropinocytosis (Ivanov, 2007). Thus, two specific
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inhibitors, chlorpromazine and MDC, were selected for further investigation. Our data
showed that MDC effectively impeded QD/sR9 internalization, while chlorpromazine at
the highest possible nontoxic concentration exhibited no inhibition of QD/sR9 uptake.
This contradiction might arise from two possibilities: 1) insufficient concentration of
chlorpromazine; or 2) blockage of other internalization pathways by MDC. The former
cannot be overcome due to apparent cytotoxicity. Blockage of other pathways by MDC
treated cells might account for the possible explanation of the discrepancy. It is known
that MDC is also an inhibitor of the transglutaminase family, which activates Rho
GTPases, the key regulators of actin assembly and dynamics (Ivanov, 2007). Thus, MDC
might block actin dependent pathways such as macropinocytosis. Because of these
limitations of the inhibitor studies, we adopted siRNA to knockdown the clathrin
pathway. The Western blot analysis indicated a complete knowdown of clathrin protein.
The QD fluorescence intensity inside cells did not differ from the control cells indicating
that clathrin-dependent pathway was not involved in QD/sR9 internalization.
Nystatin and filipin are polyene antibiotics, which create large aggregates
accumulating cholesterol and thereby sequester lipid from cell membranes. Nystatin and
filipin are highly selective inhibitors of the lipid raft dependent pathway because of lipid
sequestering. Our data showed that both inhibitors hindered the uptake of QD/sR9,
suggesting that the internalization was lipid raft dependent. Cholesterol depletion could
result in blockage of several lipid raft dependent endocytic pathways, including caveolaedependent and macropinocytosis pathways (Wadia et al., 2004). For further distinction,
caveolin-1 siRNA was chosen to knockdown caveolin-dependent pathway. The Western
blot analysis indicated a near complete knockdown of caveolin. However, live cell
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imaging indicated no reduction of QD/sR9 internalization indicating a caveolinindependent pathway of QD/sR9 internalization. Collectively, QD/sR9 internalization
occurred through a lipid raft dependent process, but was not mediated by clathrin and
caveolin.
Macropinocytosis is a rapid, lipid raft-dependent and receptor-independent form of
endocytosis. Macropinocytosis includes three essential steps: actin cytoskeleton-driven
ruffle formation, closure of the ruffle into a vesicle, and dissociation of actin filaments
from the vesicle (Swanson and Watts, 1995). The fluorescent intensities in cells treated
with two macropinocytosis inhibitors, EIPA and Cyt D, were significantly reduced,
compared to the control cells. It is worth noting that QD/sR9 was densely localized
around cellular surfaces, not in cytosol. Nakase et al. observed a similar phenomenon that
cellular R8 peptide was predominantly localized in cellular boundaries and very little
punctuate staining was observed in Cyt D treated cells (Nakase et al., 2004). Ruan et al.
also had the similar observation (Ruan et al., 2007). It is unclear how the dense
aggregates affect quantitation. Further, the mechanism of the entrapment in plasma
membranes remains to be investigated.
Collectively, our data show that sR9 can facilitate rapid cellular entry of QDs. The
process requires energy. Chathrin and Calveolin-1 are not mediators of internalization.
The major mechanism involves lipid raft and depends on macropinocytosis. Uptake
mechanisms other than clathrin, caveolea, and macropinocytosis may also be involved
and remain to be investigated. For instance, Rho family is the regulators of RhoA
dependent and CDC42 dependent pathways (Mayor and Pagano, 2007; Sandvig et al.,
2008).
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6. FUTURE WORK
In this study, the uptake mechanism of QD/sR9 was carried out. Future work will
involve several areas, including further uptake mechanism study, modifying uptake
system and organelle targeting.

6.1. OTHER UPTAKE PATHWAYS
Three main pathways of endocytosis have been investigated– clathrin-dependent
endocytosis, caveolea-dependent endocytosis, and macropinocytosis. Next other less-well
studies pathways will be focused on. Data show that QD/sR9 uptake can be inhibited by
MDC, which can block actin-dependent endocytosis via Rho family inhibition. Therefore,
other pathways involved Rho family could affect QD/sR9 uptake, such as Rho A
dependent pathway, CDC 42 dependent pathway.

6.2. ENDOSOMAL ESCAPING
Data show that QD/sR9 was entrapped in endosome (not shown), which will reduce
the function of cargoes. Therefore, endosomal escaping is the problem that we need to
resolve before we put cargoes into this delivery system. One method is using pH sensitive
peptide – HA2. The α-helix of HA2 can insert into endosome membranes at low pH
value, and then disrupt endosome membrane, which help QD/sR release from endosomes.
The other method is modifying the surface of QDs by using PEI, which can cause proton
sponge effect and let protons into endosomes resulting endosome disruption.
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6.3. ORGANELLE TARGETING
After endosomal entrapment revolved, organelle targeting will be carried out.
Because most drugs target nucleus or mitochondria, nucleus localizing signal or
mitochondria localizing peptides will be used to target nucleus or mitochondria.
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